MBX Biosciences Reports Q2 2026 Results; MBX 4291 Phase 1 Update

What Happened

• On August 6, 2026, MBX Biosciences, Inc. announced its financial results for the quarter ended June 30, 2026 (press release furnished as Exhibit 99.1) and updated its corporate presentation (furnished as Exhibit 99.2 and posted on the company website).
• The company also provided an update on its MBX 4291 Phase 1 trial, stating it remains on track to report data from the first cohort of the 12‑week multiple ascending dose portion (Part C) in Q4 2026. The first cohort is evaluating a titration regimen of 30 mg (once-weekly ×4) plus 120 mg (once-monthly) plus 180 mg (once-monthly) in adults with obesity (BMI ≥30).

Key Details

• Filing date: August 6, 2026; quarter covered: ended June 30, 2026.
• MBX 4291 Part C first‑cohort data targeted for Q4 2026.
• Dosing in the first cohort: 30 mg weekly for four weeks, then 120 mg and 180 mg once-monthly titration.
• Corporate presentation updated and available in the Investors section at www.mbxbio.com.

Why It Matters

• The Q2 results release provides the latest view of MBX’s financial condition and operating results; investors should review the press release and presentation for revenue, expense, cash position and any guidance or commentary.
• The scheduled Q4 2026 readout for MBX 4291’s Part C cohort is a near‑term clinical milestone that could affect development timelines and the company’s program value.
• The filing includes standard forward‑looking statements and risk disclosures—actual outcomes may differ due to development, regulatory, financial and operational risks described in MBX’s SEC filings. Investors should consult the full 8‑K exhibits and recent SEC reports for detailed financials and risk factors.